Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 6Phase 1 6Phase NA 3Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Unknown 3Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 6Endocrine 2

Conditions

Thyroid Neoplasms 3Thyroid Nodule 1Low Risk Differentiated Thyroid Cancer 1Hyperthyroidism 1Differentiated Thyroid Cancer 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Iodine-131 × Clear all
NCT05142904 2025-07-17

RABITO

Rijnstate Hospital

Phase 3 Terminated
40 enrolled
Head & Neck

Hyperthyroidism, Thyroid Nodule

NCT04964284 2023-10-23

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Unknown
328 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01837745 2023-05-17

ESTIMABL2

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Active not recruiting
776 enrolled
EndocrineHead & Neck

Low Risk Differentiated Thyroid Cancer

NCT05468554 2022-10-19

METHYR

Medical University of Bialystok

Phase 3 Unknown
160 enrolled
Head & Neck

Thyroid Neoplasms

NCT00115895 2018-03-02

The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy

University of Helsinki

Phase 3 Unknown
160 enrolled
Head & Neck

Thyroid Neoplasms

NCT00196729 2015-03-18

Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration

Sanofi

Phase 3 Completed
63 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡